ANTITUMOR EFFECTS OF POLYVALENT AND MONOVALENT VACCINES COUPLED WITH INTERLEUKIN-2 IN A METASTATIC MELANOMA MODEL

被引:0
作者
SHRAYER, D
KONESS, J
KOUTTAB, N
BOGAARS, H
HEARING, VJ
MAIZEL, A
WANEBO, HJ
机构
[1] BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,PROVIDENCE,RI 02908
[2] BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT SURG,PROVIDENCE,RI 02908
[3] NCI,CELL BIOL LAB,BETHESDA,MD 20892
关键词
MELANOMA; POLYVALENT ANTIGEN; POLYCLONAL ANTIBODY; INTERLEUKIN-2; IMMUNIZATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously reported that preimmunization of mice with formalinized extracellular antigens (fECA) derived from melanoma cells, in combination with interleukin 2 (IL-2) treatment and surgical resection, decreased subsequent tumor growth and increased survival of mice in a new model for spontaneous metastasis of melanoma. In this study, we have modified the sequence of tumor growth and therapy to more closely mimic the clinical situation. Mice were challenged subcutaneously in the tail with 5 x 10(5) B16 F10 melanoma cells and, by day 21, all of them had developed localized melanoma tumors. The primary tumor-bearing tails of control and experimental animals were then resected distal to the base of the tail, and therapy of the mice was initiated the following day. Groups of mice received different polyvalent and monovalent murine melanoma vaccines (including native or formalin treated extracellular antigens, intact melanoma cells, or purified B700 antigen), with or without concomitant low doses of IL-2. The results demonstrate that the vaccine therapies elicited significant increases in survival of the mice, accompanied by reductions in the size of lymph nodes and in the number of pulmonary metastases. These effects, particularly with the intact melanoma cell vaccine, could be improved even further with concomitant IL-2 treatment.
引用
收藏
页码:1121 / 1127
页数:7
相关论文
共 21 条
[1]  
BYSTRYN JC, 1992, CANCER RES, V52, P5948
[2]  
BYSTRYN JC, 1992, CANCER-AM CANCER SOC, V69, P1157, DOI 10.1002/cncr.2820690516
[3]  
BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO
[4]  
2-L
[5]   SEARCH FOR ANTIMETASTATIC THERAPY - EFFECTS OF PHENYTOIN ON B16 MELANOMA METASTASIS [J].
DYCE, M ;
SHARIF, SF ;
WHALEN, GF ;
KARAKOUSIS, CP .
JOURNAL OF SURGICAL ONCOLOGY, 1992, 49 (02) :107-112
[6]  
FUJIWARA T, 1990, CANCER RES, V50, P7003
[7]   THE INTRACELLULAR ASSOCIATION OF B700 AND B50 MURINE MELANOMA ANTIGENS AND THEIR ROLE IN TUMOR REJECTION [J].
GERSTEN, DM ;
WILLIAMS, LJ ;
MOODY, D ;
MONTAGUE, PM ;
LAW, LW ;
HEARING, VJ .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) :497-500
[8]   VACCINES CONTAINING PURIFIED GM2 GANGLIOSIDE ELICIT GM2 ANTIBODIES IN MELANOMA PATIENTS [J].
LIVINGSTON, PO ;
NATOLI, EJ ;
CALVES, MJ ;
STOCKERT, E ;
OETTGEN, HF ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (09) :2911-2915
[9]  
LIVINGSTON PO, 1989, CANCER RES, V49, P7045
[10]   MELANOMA TUMOR VACCINE - 5-YEAR FOLLOW-UP [J].
MCGEE, JMC ;
LYTLE, GH ;
MALNAR, KF ;
PRICE, JA ;
HUMPHREY, LJ .
JOURNAL OF SURGICAL ONCOLOGY, 1991, 47 (04) :233-238